Here are four things to know.
- Jason Malek, former president of Heritage, and Jeffrey Glazer, former chairman and CEO of the drug company, were charged in December for conspiring to fix generic drug prices.
- Prosecuters alleged the two executives participated in a scheme to fix prices for the antibiotic doxycycline hyclate and the diabetes medication glyburide, artificially driving up costs for patients.
- In January, the two men pled guilty to the federal criminal charges, reports Reuters.
- As part of the settlement, Mr. Malek and Mr. Glazer will each pay a $25,000 civil penalty and cooperate with an ongoing state investigation, according to the report.
More articles on supply chain:
Biogen offshoot to acquire rare disease biotech for $400M: 4 things to know
Why FDA’s newest approval paves the way for precision medicine
Supply chain tip of the day: How pharmacy can drive revenue for a health system post-merger
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
